Search for other works by this author on: ...

Treatment with a BRAF inhibitor of unresectable or metastatic melanoma with a BRAF V600E or V600K mutation has an estimated 5-year survival rate of 34%, with 19% being progression free. To improve ...

为解决BRAF p.V600E突变在甲状腺乳头状癌(PTC)风险分层中的争议，芝加哥大学团队通过301例患者队列研究，结合免疫组化(VE1克隆)和分子检测，发现该突变(78.7%)与形态学亚型显著相关，但未独立预测复发。大体积淋巴结转移(HR 3.37)和男性(HR 2.29)才是复发关键因素 ...

初步评估显示其甲状腺左叶存在一个 3.8 cm的结节，细针穿刺细胞学检查归类为Bethesda III类。通过定量聚合酶链反应（qPCR）检测发现BRAF V600E突变，提示甲状腺乳头状癌（PTC）可能。基于BRAF V600E突变的检测，术前诊断为甲状腺乳头状癌。患者接受了甲状腺切除术及 ...

其中，BRAF 激活突变在约 10% 的转移性结直肠癌中出现，这些患者对标准化疗反应不佳，预后较差。BRAF V600E 突变会激活丝裂原活化蛋白激酶（Mitogen-Activated Protein Kinase，MAPK）信号通路，这也成为了靶向治疗的重点目标。目前，BRAF（恩考芬尼 encorafenib）和表皮生长 ...

Of these global cases, 10% will have a BRAF V600E gene mutation implicated in carcinogenesis pathways and have a poor prognosis compared to other subtypes of CRC, such as KRAS mutations.